Also found in: Dictionary, Thesaurus, Financial, Acronyms, Encyclopedia, Wikipedia.
Pharmacologic class: Mineral
Therapeutic class: Dietary supplement, electrolyte replacement agent
Pregnancy risk category C (calcium acetate, chloride, glubionate, gluceptate, phosphate), NR (calcium carbonate, citrate, gluconate, lactate)
Increases serum calcium level through direct effects on bone, kidney, and GI tract. Decreases osteoclastic osteolysis by reducing mineral release and collagen breakdown in bone.
Gelcaps: 667 mg
Tablets: 667 mg
Capsules: 1,250 mg
Lozenges: 600 mg
Oral suspension: 1,250 mg
Powder: 6.5 g
Tablets: 650 mg, 1,250 mg, 1,500 mg
Tablets (chewable): 750 mg, 1,000 mg, 1,250 mg
Tablets (gum): 300 mg, 450 mg, 500 mg
Injection: 10% solution
Tablets: 950 mg
Injection: 22% solution
Injection: 10% solution
Tablets: 500 mg, 650 mg, 975 mg
Tablets: 325 mg, 650 mg
Tablets: 600 mg
Indications and dosages
➣ Hypocalcemic emergency
Adults: 7 to 14 mEq I.V. of 10% calcium gluconate solution, 2% to 10% calcium chloride solution, or 22% calcium gluceptate solution
Children: 1 to 7 mEq calcium gluconate I.V.
Infants: Up to 1 mEq calcium gluconate I.V.
➣ Hypocalcemic tetany
Adults: 4.5 to 16 mEq calcium gluconate I.V., repeated as indicated until tetany is controlled
Children: 0.5 to 0.7 mEq/kg calcium gluconate I.V. three to four times daily as indicated until tetany is controlled
Neonates: 2.4 mEq/kg calcium gluconate I.V. daily in divided doses
➣ Cardiac arrest
Adults: 0.027 to 0.054 mEq/kg calcium chloride I.V., 4.5 to 6.3 mEq calcium gluceptate I.V., or 2.3 to 3.7 mEq calcium gluconate I.V.
Children: 0.27 mEq/kg calcium chloride I.V., repeated in 10 minutes if needed. Check calcium level before giving additional doses.
➣ Magnesium intoxication
Adults: Initially, 7 mEq I.V.; subsequent dosages based on patient response
➣ Exchange transfusions
Adults: 1.35 mEq calcium gluconate I.V. with each 100 ml of citrated blood
➣ Hyperphosphatemia in patients with end-stage renal disease
Adults: Two tablets P.O. daily, given in divided doses t.i.d. with meals. May increase gradually to bring serum phosphate level below 6 mg/dl, provided hypercalcemia doesn't develop.
➣ Dietary supplement
Adults: 500 mg to 2 g P.O. daily
• Hypersensitivity to drug
• Ventricular fibrillation
• Hypercalcemia and hypophosphatemia
• Renal calculi
• Pregnancy or breastfeeding
Use cautiously in:
• renal insufficiency, pernicious anemia, heart disease, sarcoidosis, hyperparathyroidism, hypoparathyroidism
• history of renal calculi
☞ When infusing I.V., don't exceed a rate of 200 mg/minute.
• Keep patient supine for 15 minutes after I.V. administration to prevent orthostatic hypotension.
• Administer P.O. doses 1 to 1½ hours after meals.
• Know that I.M. or subcutaneous administration is never recommended.
• Be aware that I.V. route is preferred in children.
• Be alert for extravasation, which causes tissue necrosis.
CNS: headache, weakness, dizziness, syncope, paresthesia
CV: mild blood pressure decrease, bradycardia, arrhythmias, cardiac arrest (with rapid I.V. injection)
GI: nausea, vomiting, diarrhea, constipation, epigastric pain or discomfort
GU: urinary frequency, renal calculi
Musculoskeletal: joint pain, back pain
Other: altered or chalky taste, excessive thirst, allergic reactions (including facial flushing, swelling, tingling, tenderness in hands, and anaphylaxis)
Drug-drug. Atenolol, fluoroquinolones, tetracycline: decreased bioavailability of these drugs
Calcium channel blockers: decreased calcium effects
Cardiac glycosides: increased risk of cardiac glycoside toxicity
Iron salts: decreased iron absorption
Sodium polystyrene sulfonate: metabolic alkalosis
Verapamil: reversal of verapamil effects
Drug-diagnostic tests. Calcium: increased level
Drug-food. Foods containing oxalic acid (such as spinach), phytic acid (such as whole grain cereal), or phosphorus (such as dairy products): interference with calcium absorption
• Monitor calcium levels frequently, especially in elderly patients.
• Instruct patient to consume plenty of milk and dairy products during therapy.
• Refer patient to dietitian for help in meal planning and preparation.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.
calcium carbonate(kal-see-um kar-bo-nate) ,
Liquid Cal-600(trade name),
Maalox Antacid Caplets(trade name),
Mylanta Lozenges(trade name),
Rolaids Calcium Rich(trade name),
Surpass Extra Strength(trade name),
Tums E-X(trade name)
ClassificationTherapeutic: mineral electrolyte replacements supplements
Time/action profile (effects on serum calcium)
Adverse Reactions/Side Effects
Central nervous system
- arrhythmias (most frequent)
- constipation (most frequent)
Drug-Drug interactionHypercalcemia increases the risk of digoxin toxicity.Chronic use with antacids in renal insufficiency may lead to milk-alkali syndrome.Ingestion by mouth decreases the absorption of orally administered tetracyclines, fluoroquinolones, phenytoin, and iron salts.Excessive amounts may decrease the effects of calcium channel blockers.Decreases absorption of etidronate and risedronate (do not take within 2 hr of calcium supplements).May decrease the effectiveness of atenolol.Concurrent use with diuretics (thiazide) may result in hypercalcemia.May decrease the ability of sodium polystyrene sulfonate to decrease serum potassium.Cereals, spinach, or rhubarb may decrease the absorption of calcium supplements.Calcium acetate should not be given concurrently with other calcium supplements.
Route/Dosage1 gram of calcium carbonate contains 400 mg elemental calcium (20 mEq calcium). Doses expressed in terms of elemental calcium.
- Calcium Supplement/Replacement: Observe patient closely for symptoms of hypocalcemia (paresthesia, muscle twitching, laryngospasm, colic, cardiac arrhythmias, Chvostek’s or Trousseau’s sign). Notify physician or other health care professional if these occur. Protect symptomatic patients by elevating and padding siderails and keeping bed in low position.
- Monitor patient on digitalis glycosides for signs of toxicity.
- Antacid: When used as an antacid, assess for heartburn, indigestion, and abdominal pain. Inspect abdomen; auscultate bowel sounds.
- Lab Test Considerations: Monitor serum calcium or ionized calcium, chloride, sodium, potassium, magnesium, albumin, and parathyroid hormone (PTH) concentrations before and periodically during therapy for treatment of hypocalcemia.
Assess patient for nausea, vomiting, anorexia, thirst, severe constipation, paralytic ileus, and bradycardia. Contact physician or other health care professional immediately if these signs of hypercalcemia occur.
- May cause decreased serum phosphate concentrations with excessive and prolonged use. When used to treat hyperphosphatemia in renal failure patients, monitor phosphate levels.
Potential Nursing DiagnosesImbalanced nutrition: less than body requirements (Indications)
Risk for injury, related to osteoporosis or electrolyte imbalance (Indications)
- Oral: Administer calcium carbonate 1–1.5 hr after meals and at bedtime. Chewable tablets should be well chewed before swallowing. Dissolve effervescent tablets in glass of water. Follow oral doses with a full glass of water, except when using calcium carbonate as a phosphate binder in renal dialysis. Administer on an empty stomach before meals to optimize effectiveness in patients with hyperphosphatemia.
- Instruct patient not to take enteric-coated tablets within 1 hr of calcium carbonate; this will result in premature dissolution of the tablets.
- Do not administer concurrently with foods containing large amounts of oxalic acid (spinach, rhubarb), phytic acid (brans, cereals), or phosphorus (milk or dairy products). Administration with milk products may lead to milk-alkali syndrome (nausea, vomiting, confusion, headache). Do not take within 1–2 hr of other medications if possible.
- Instruct patients on a regular schedule to take missed doses as soon as possible, then go back to regular schedule.
- Advise patient that calcium carbonate may cause constipation. Review methods of preventing constipation (increasing bulk in diet, increasing fluid intake, increasing mobility) and using laxatives. Severe constipation may indicate toxicity.
- Advise patient to avoid excessive use of tobacco or beverages containing alcohol or caffeine.
- Calcium Supplement: Encourage patients to maintain a diet adequate in vitamin D (see ).
- Osteoporosis: Advise patients that exercise has been found to arrest and reverse bone loss. Patient should discuss any exercise limitations with health care professional before beginning program.
- Increase in serum calcium levels.
- Decrease in the signs and symptoms of hypocalcemia.
- Resolution of indigestion.
- Control of hyperphosphatemia in patients with renal failure.